JP2025511352A5 - - Google Patents
Info
- Publication number
- JP2025511352A5 JP2025511352A5 JP2024558455A JP2024558455A JP2025511352A5 JP 2025511352 A5 JP2025511352 A5 JP 2025511352A5 JP 2024558455 A JP2024558455 A JP 2024558455A JP 2024558455 A JP2024558455 A JP 2024558455A JP 2025511352 A5 JP2025511352 A5 JP 2025511352A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- gdc
- product according
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263328149P | 2022-04-06 | 2022-04-06 | |
| US63/328,149 | 2022-04-06 | ||
| PCT/US2023/017455 WO2023196329A1 (en) | 2022-04-06 | 2023-04-04 | Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511352A JP2025511352A (ja) | 2025-04-15 |
| JP2025511352A5 true JP2025511352A5 (cg-RX-API-DMAC10.html) | 2026-03-24 |
Family
ID=86286527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024558455A Pending JP2025511352A (ja) | 2022-04-06 | 2023-04-04 | がんの処置のためのｇｄｃ－６０３６およびｇｄｃ－００７７を含む併用療法 |
Country Status (13)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250000802A1 (en) * | 2023-06-09 | 2025-01-02 | Hoffmann-La Roche Inc. | Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111909173B (zh) | 2015-07-02 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法 |
| KR20210035211A (ko) * | 2018-07-23 | 2021-03-31 | 에프. 호프만-라 로슈 아게 | Pi3k 저해제인 gdc-0077로 암을 치료하는 방법 |
| WO2020097537A2 (en) | 2018-11-09 | 2020-05-14 | Genentech, Inc. | Fused ring compounds |
| TWI829003B (zh) | 2020-08-12 | 2024-01-11 | 美商建南德克公司 | 喹唑啉化合物之合成 |
| EP4243827A1 (en) | 2020-11-13 | 2023-09-20 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer |
| KR102975432B1 (ko) | 2020-11-13 | 2026-06-10 | 제넨테크, 인크. | 고형 종양 치료를 위한 krasg12c 억제제 및 vegf 억제제를 포함하는 방법 및 조성물 |
| TWI895563B (zh) | 2020-12-08 | 2025-09-01 | 美商建南德克公司 | 用於治療實性瘤之包含ｋｒａｓｇ１２ｃ抑制劑及ｅｇｆｒ抑制劑之組成物及方法 |
| AR128449A1 (es) | 2022-02-07 | 2024-05-08 | Genentech Inc | Proceso para la síntesis de compuestos de quinazolina |
| CN118742544A (zh) | 2022-02-07 | 2024-10-01 | 基因泰克公司 | 1-((s)-4-((r)-7-(6-氨基-4-甲基-3-(三氟甲基)吡啶-2-基)-6-氯-8-氟-2-(((s)-1-甲基吡咯烷-2-基)甲氧基)喹唑啉-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的固体形式 |
-
2023
- 2023-04-04 PL PL23721096.8T patent/PL4504202T3/pl unknown
- 2023-04-04 CN CN202380032303.9A patent/CN119013026A/zh active Pending
- 2023-04-04 AU AU2023249068A patent/AU2023249068A1/en active Pending
- 2023-04-04 CA CA3255718A patent/CA3255718A1/en active Pending
- 2023-04-04 JP JP2024558455A patent/JP2025511352A/ja active Pending
- 2023-04-04 US US18/295,550 patent/US12383557B2/en active Active
- 2023-04-04 KR KR1020247032867A patent/KR20240167654A/ko active Pending
- 2023-04-04 ES ES23721096T patent/ES3067080T3/es active Active
- 2023-04-04 IL IL315250A patent/IL315250A/en unknown
- 2023-04-04 WO PCT/US2023/017455 patent/WO2023196329A1/en not_active Ceased
- 2023-04-04 EP EP23721096.8A patent/EP4504202B1/en active Active
- 2023-04-06 TW TW112112927A patent/TW202345846A/zh unknown
-
2024
- 2024-10-03 MX MX2024012230A patent/MX2024012230A/es unknown
-
2025
- 2025-07-14 US US19/268,721 patent/US20260053802A1/en not_active Abandoned